vaccines living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID-19 severe or critically

	COVID-19 prophylaxis (excluding children)
vaccines	Reynolds
A EFFACER_sequential Immunization	NCT04833101
BCG vaccination	NCT04648800 Tsilika
CoVLP (MT-2766, Medicago)	Hager ...
first booster dose	Pfizer/BioNTech Booster study C4591031- first boost C4591031- first boost
mRNA vaccine (any) - first boost
Comirnaty - first boost	C4591031- first boost C4591031- first boost
heterologous prime-boost	CombiVacS
Inactivated virus vaccine
CoronaVac (SinoVac)	DOUBLON SinoVac-PROFISCOV phase 3 Zhang PROFISCOV ... Wu Sinovac Turkish Trial
Covaxin, Bharat Biotech (BBV152)	Ella
Sinopharm Beijing (BBIBP-CorV)	Xia ... Kanokudom
Sinopharm Wuhan	Sinopharm Wuhan Vero cell Xia ...
mRNA vaccine	Nakahara Fraiman
Comirnaty (tozinameran - Pfizer/BIONTECH)	BNT162b2 phase 3 ... Haas Watanabe xie Lustig Kanokudom
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)	COVE Moderna/NIH phase 3 ... Moderna study 201 100µg
Non replicating viral vector	Pitisuttithum
CanSino (Convidecia)	CanSino phase 3 CanSino phase 2 ... Fengcai Li J NCT04540419
Covishield (Oxford/AZ formulation)	Kulkarni
Janssen AD26 vaccine (JNJ-78436735)	Sadoff ENSEMBLE ... Reindl-Schwaighofer Sisonke study ...
Sputnik V (Gam-COVID-Vac)	RESIST ...
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	AstraZeneca phase 3 US ... Folegatti ChAdOx1 phase 3 ... COV005 John Com-COV ComFluCOV ... Bonelli Com-COV2 Asano AstraZeneca Oxford pooled analysis ... Kanokudom AstraZeneca phase 3 US ... Valim
protein subunit vaccine	Chappell Meng Shu Shinkai Liu
Nuvaxovid (NVX-CoV2373) Novavax	Novavax phase 3 UK ... Keech Novavax PREVEND-19 phase 3 US ... Novavax phase 2 South Africa ...
Replicating Viral Vector	Vanhoutte
seasonal influenza vaccines	ComFluCOV ...

86 studies excluded by filtering options 1

4830	NCT04276896, 0	2	30	0	excluded	not a RCT	risk of bias not avaialble
5493	de Chaisemartin C, 2020	0	12	0	selection pending
5631	Weng, 0	0	13	0	selection pending
6486	CoVEHPI (Israel), 0	0	10	0	selection pending
6729	Shah, 2021	1	13	3		not a RCT	high risk of bias
6787	Thompson, 2021	1	10	4		not a RCT	high risk of bias
6788	Waissengrin, 2021	0	13	0	selection pending
6790	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6791	Tande, 0	1	13	0		not a RCT	risk of bias not avaialble
6894	Andrejko, 2021	1	20	0		not a RCT	risk of bias not avaialble
6927	Rossman, 2021	0	13	0	selection pending
6931	Yair, 2921	1	32	0		not a RCT	risk of bias not avaialble
6934	Boyarsky, 2021	1	32	0		not a RCT	risk of bias not avaialble
6949	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6966	Ou, 2021	2	32	0	excluded	not a RCT	risk of bias not avaialble
6981	Public Health England (Harris), 2021	1	13	3		not a RCT	high risk of bias
7001	Boyarsky, 2021	1	32	0		not a RCT	risk of bias not avaialble
7025	Haberman, 2021	0	13	0	selection pending
7037	Agur, 0	1	10	0		not a RCT	risk of bias not avaialble
7052	Aleman, 2021	1	32	0		not a RCT	risk of bias not avaialble
7069	Hillus, 2021	0	10	0	selection pending
7070	PHE variants (Technical briefing 12 22 may 2021), 2021	2	20	2	excluded	not a RCT
7100	Chung, 2021	1	20	0		not a RCT	risk of bias not avaialble
7325	Skowronski, 2021	0	13	0	selection pending
7419	Scotland delta (Sheikh), 2021	1	20	3		not a RCT	high risk of bias
7420	PHE (Stowe), 2021	2	13	3	excluded	not a RCT	high risk of bias
7950	Harris, 2021	1	13	3		not a RCT	high risk of bias
8143	Butt, 2021	1	20	2		not a RCT
8145	Normark, 2021	0	10	0	selection pending
8147	Canada (Nasreen), 2021	1	20	2		not a RCT
8149	PHE Technical briefing 16 (11/18 June 2021), 2021	2	13	3	excluded	not a RCT	high risk of bias
8150	Ramasamy, 2021	0	32	0	selection pending
8164	Public Health England, May 16, 2021 (Bernal), 2021	1	20	2		not a RCT
8248	Montgomery, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8255	REACT-SCOT, 2021	1	20	0		not a RCT	risk of bias not avaialble
8272	Martinez-Baz, 2021	1	13	0		not a RCT	risk of bias not avaialble
8274	REACT-1 round 13 final report (Elliott, Imperial College London), 2021	1	13	3		not a RCT	high risk of bias
8275	Musser, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8294	CDC Mesa County, Colorado, 2021	1	13	3		not a RCT	high risk of bias
8320	Mayo Clinic (Puranik), 2021	1	13	3		not a RCT	high risk of bias
8333	Qatar (Tang), 2021	1	20	3		not a RCT	high risk of bias
8350	Rosenberg, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8356	Li, 2021	1	20	4		not a RCT	high risk of bias
8359	Oxford (Pouwels), 2021	1	13	2		not a RCT
8360	HEROES-RECOVER (Fowlkes), 2021	1	13	3		not a RCT	high risk of bias
8513	Grannis, 2021	1	20	3		not a RCT	high risk of bias
8514	VA (Bajema), 2021	1	20	3		not a RCT	high risk of bias
8515	Scobie, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
8516	Bar-On, 2021	1	11	0		not a RCT	risk of bias not avaialble
9065	Ruddy, 2021	2	32	0	excluded	not a RCT	risk of bias not avaialble
9132	Arbel, 2021	1	13	3		not a RCT	high risk of bias
9170	UKHSA report 33 (23 december 2021), 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9173	Sisonke 2 (booster), 2021	1	20	0		not a RCT	risk of bias not avaialble
9174	Barda, 2021	1	13	0		not a RCT	risk of bias not avaialble
9175	Patalon, 2021	1	20	0		not a RCT	risk of bias not avaialble
9176	UKHSA 31 december 2021, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9183	Mattiuzzi, 2022	1	15	0		not a RCT	risk of bias not avaialble
9203	England (Andrews), 2021	1	20	0		not a RCT	risk of bias not avaialble
9210	Ontario (Buchan), 2022	1	20	0		not a RCT	risk of bias not avaialble
9213	COVI3, 2022	1	10	0		not a RCT	risk of bias not avaialble
9214	Southern California (Lewnard), 2022	2	13	0	excluded	not a RCT	risk of bias not avaialble
9216	Sultan, 2022	0	12	0	selection pending
9267	Ostropolets, 2021	0	12	0	selection pending
9288	Kislaya, 2022	1	11	0		not a RCT	risk of bias not avaialble
9290	Danza, 2022	2	32	0	excluded	not a RCT	risk of bias not avaialble
9293	Tenforde, 2022	1	20	0		not a RCT	risk of bias not avaialble
9293	Tenforde, 2022	1	20	0		not a RCT	risk of bias not avaialble
9294	UKHSA (report W4- 27 January), 2022	2	12	0	excluded	not a RCT	risk of bias not avaialble
9316	Shibli, 2021	1	13	0		not a RCT	risk of bias not avaialble
9331	McConeghy, 2022	1	10	0		not a RCT	risk of bias not avaialble
9331	McConeghy, 2022	1	10	0		not a RCT	risk of bias not avaialble
9341	EPIPHAR (ARN) DUPLICATE, 2022	0	12	0	selection pending
9409	Thompson -VISIOn Network (omicron), 2022	1	12	0		not a RCT	risk of bias not avaialble
9410	Thompson -VISIOn Network (delta), 2022	0	12	0	selection pending
9411	Accorsi, 2022	1	12	0		not a RCT	risk of bias not avaialble
9411	Accorsi, 2022	1	12	0		not a RCT	risk of bias not avaialble
9415	Patalon, 2022	1	20	0		not a RCT	risk of bias not avaialble
9461	Abu-Raddad, 2022	1	13	0		not a RCT	risk of bias not avaialble
9461	Abu-Raddad, 2022	1	13	0		not a RCT	risk of bias not avaialble
9478	Lauring, 2022	1	20	0		not a RCT	risk of bias not avaialble
9487	Shemer, 2021	1	11	0		not a RCT	risk of bias not avaialble
9491	Li X, 2022	1	12	0		not a RCT	risk of bias not avaialble
9584	McMurry, 2021	1	13	0		not a RCT	risk of bias not avaialble
9589	Kirsebom (UKHSA), 2022	1	13	0		not a RCT	risk of bias not avaialble
9590	UKHSA report week 12 (24 March 2022), 2022	1	12	0		not a RCT	risk of bias not avaialble
9629	Le Vu S. (EPI-PHARE), 2021	0	12	0	selection pending